Why man's best friend, the dog, could also benefit from an anti‑HER-2 vaccine (Review)
- Authors:
- Judit Fazekas
- Irene Fürdös
- Josef Singer
- Erika Jensen‑Jarolim
-
Affiliations: Comparative Medicine, The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna 1210, Austria - Published online on: August 11, 2016 https://doi.org/10.3892/ol.2016.5001
- Pages: 2271-2276
-
Copyright: © Fazekas et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Tan M, Yao J and Yu D: Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57:1199–1205. 1997.PubMed/NCBI | |
|
Yu D and Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 19:6115–6121. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z: HER2//PI-3K//Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 357:39–51. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA and Wolmark N: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 29:3366–3373. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Singh JC, Jhaveri K and Esteva FJ: HER2-positive advanced breast cancer: Optimizing patient outcomes and opportunities for drug development. Br J Cancer. 111:1888–1898. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rimawi MF, Schiff R and Osborne CK: Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 66:111–128. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, et al: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 372:724–734. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mukohara T: Role of HER2-targeted agents in adjuvant treatment for breast cancer. Chemother Res Pract. 2011:7303602011.PubMed/NCBI | |
|
deAzambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 15:1137–1146. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, et al: Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 22:1301–1309. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, et al: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 15:3856–3865. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Paoloni M and Khanna C: Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 8:147–156. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gamba CO, Dias EJ, Ribeiro LG, Campos LC, Estrela-Lima A, Ferreira E and Cassali GD: Histopathological and immunohistochemical assessment of invasive micropapillary mammary carcinoma in dogs: A retrospective study. Vet J. 196:241–246. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ressel L, Puleio R, Loria GR, Vannozzi I, Millanta F, Caracappa S and Poli A: HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome. Res Vet Sci. 94:299–305. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Muhammadnejad A, Keyhani E, Mortazavi P, Behjati F and Haghdoost IS: Overexpression of her-2/neu in malignant mammary tumors; translation of clinicopathological features from dog to human. Asian Pac J Cancer Prev. 13:6415–6421. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JH, Im KS, Kim NH, Yhee JY, Nho WG and Sur JH: Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: Histopathological and immunohistochemical study. Vet J. 189:318–322. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Singer J, Weichselbaumer M, Stockner T, Mechtcheriakova D, Sobanov Y, Bajna E, Wrba F, Horvat R, Thalhammer JG, Willmann M and Jensen-Jarolim E: Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol. 50:200–209. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Peña L, Gama A, Goldschmidt MH, Abadie J, Benazzi C, Castagnaro M, Díez L, Gärtner F, Hellmén E, Kiupel M, et al: Canine mammary tumors: A review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry. Vet Pathol. 51:127–145. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pichler WJ: Adverse side-effects to biological agents. Allergy. 61:912–920. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Corominas M, Gastaminza G and Lobera T: Hypersensitivity reactions to biological drugs. J Investig Allergol Clin Immunol. 24:212–225. 2014.PubMed/NCBI | |
|
Baldo BA: Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology. 2:e263332013. View Article : Google Scholar : PubMed/NCBI | |
|
Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner W, Meitz S, Mechtcheriakova D, Sobanov Y, et al: Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. Mol Cancer Ther. 13:1777–1790. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rue SM, Eckelman BP, Efe JA, Bloink K, Deveraux QL, Lowery D and Nasoff M: Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma. Vet Immunol Immunopathol. 164:148–159. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jensen-Jarolim E and Singer J: Cancer vaccines inducing antibody production: More pros than cons. Expert Rev Vaccines. 10:1281–1289. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Milani A, Sangiolo D, Montemurro F, Aglietta M and Valabrega G: Active immunotherapy in HER2 overexpressing breast cancer: Current status and future perspectives. Ann Oncol. 24:1740–1748. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson KS: Tumor vaccines for breast cancer. Cancer Invest. 27:361–368. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, et al: AE37: A novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther. 11:1543–1550. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
NCT01730118, . Ad/HER2/Neu dendritic cell cancer vaccine testing. https://clinicaltrials.gov/Accessed. August 31–2015 | |
|
Knittelfelder R, Riemer AB and Jensen-Jarolim E: Mimotope vaccination-from allergy to cancer. Expert Opin Biol Ther. 9:493–506. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ashok BT, David L, Chen YG, Garikapaty VP, Chander B, Kanduc D, Mittelman A and Tiwari RK: Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer. Int J Mol Med. 11:465–471. 2003.PubMed/NCBI | |
|
Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC and Jensen-Jarolim E: Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst. 97:1663–1670. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Riemer AB, Kraml G, Scheiner O, Zielinski CC and Jensen-Jarolim E: Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu-a new method of epitope definition. Mol Immunol. 42:1121–1124. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC and Jensen-Jarolim E: Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol. 173:394–401. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Manzano-Szalai K, Thell K, Willensdorfer A, Weghofer M, Pfanzagl B, Singer J, Ritter M, Stremnitzer C, Flaschberger I, Michaelis U and Jensen-Jarolim E: Adeno-associated virus-like particles as new carriers for B-cell vaccines: Testing immunogenicity and safety in BALB/c mice. Viral Immunol. 27:438–448. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Singer J, Manzano-Szalai K, Fazekas J, Thell K, Bentley-Lukschal A, Stremnitzer C, Roth-Walter F, Weghofer M, Ritter M, Tossi KP, et al: Proof of concept study with a HER-2 mimotope anti-cancer vaccine deduced from a novel AAV-mimotope library platform. Oncoimmunology. e11714462016. View Article : Google Scholar | |
|
Valicsek E, Kószó R, Dobi Á, Uhercsák G, Varga Z, Vass A, Jebelovszky É and Kahán Z: Cardiac surveillance findings during adjuvant and palliative trastuzumab therapy in patients with breast cancer. Anticancer Res. 35:4967–4973. 2015.PubMed/NCBI | |
|
Dobson JM, Samuel S, Milstein H, Rogers K and Wood JL: Canine neoplasia in the UK: Estimates of incidence rates from a population of insured dogs. J Small Anim Pract. 43:240–246. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Arnold-Gloor S, Hubler M and Reichler I: Diseases of the mammary glandPlacement of teh dog clinic. Suter PF, Arnold-Gloor S and Niemand HG: Parey; Stuttgart: pp. 881–883. 2006, (In German). | |
|
Baba AI, Câtoi C and Baba AI: Mammary gland tumours-comparative oncology. The publishing house of the Romanian academy; Bucharest: pp. 1online resource. 2007, https://www.ncbi.nlm.nih.gov/books/NBK9557/Accessed August 31, 2015. | |
|
Sorenmo K: Canine mammary gland tumors. Vet Clin North Am Small Anim Pract. 33:573–596. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Novosad CA: Principles of treatment for mammary gland tumors. Clin Tech Small Anim Pract. 18:107–109. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Queiroga FL, Raposo T, Carvalho MI, Prada J and Pires I: Canine mammary tumours as a model to study human breast cancer: Most recent findings. In vivo. 25:455–465. 2011.PubMed/NCBI | |
|
de Las Mulas JM, Millán Y and Dios R: A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol. 42:200–212. 2005. View Article : Google Scholar | |
|
Queiroga FL, Pérez-Alenza MD, Silvan G, Peña L, Lopes C and Illera JC: Role of steroid hormones and prolactin in canine mammary cancer. J Steroid Biochem Mol Biol. 94:181–187. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Torres CG, Pino AM and Sierralta WD: A cyclized peptide derived from alpha fetoprotein inhibits the proliferation of ER-positive canine mammary cancer cells. Oncol Rep. 21:1397–1404. 2009.PubMed/NCBI | |
|
Wakui S, Muto T, Yokoo K, Yokoo R, Takahashi H, Masaoka T, Hano H and Furusato M: Prognostic status of p53 gene mutation in canine mammary carcinoma. Anticancer Res. 21:611–616. 2001.PubMed/NCBI | |
|
Lee CH and Kweon OK: Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors. J Vet Sci. 3:321–325. 2002.PubMed/NCBI | |
|
Carvalho MI, Pires I, Prada J and Queiroga FL: A role for T-lymphocytes in human breast cancer and in canine mammary tumors. Biomed Res Int. 2014:1308942014. View Article : Google Scholar : PubMed/NCBI | |
|
Haga S, Nakayama M, Tatsumi K, Maeda M, Imai S, Umesako S, Yamamoto H, Hilgers J and Sarkar NH: Overexpression of the p53 gene product in canine mammary tumors. Oncol Rep. 8:1215–1219. 2001.PubMed/NCBI | |
|
Tao JJ, Visvanathan K and Wolff AC: Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast. 24(Suppl 2): S149–S153. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bracha S, Walshaw R, Danton T, Holland S, Ruaux C and Obradovich J: Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma. J Small Anim Pract. 55:369–374. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Selmic LE, Burton JH, Thamm DH, Withrow SJ and Lana SE: Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J Vet Intern Med. 28:554–563. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Stratmann N, Failing K, Richter A and Wehrend A: Mammary tumor recurrence in bitches after regional mastectomy. Vet Surg. 37:82–86. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Betz D, Schoenrock D, Mischke R, Baumgärtner W and Nolte I: Postoperative treatment outcome in canine mammary tumors. Multivariate analysis of the prognostic value of pre- and postoperatively available information. Tierarztl Prax Ausg K Kleintiere Heimtiere. 40:235–242. 2012.(In English, German). PubMed/NCBI | |
|
Hay M, Thomas DW, Craighead JL, Economides C and Rosenthal J: Clinical development success rates for investigational drugs. Nat Biotechnol. 32:40–51. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Marchetti S and Schellens JH: The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer. 97:577–581. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Stapff M: Drug trials: An introduction to clinical trials for doctors, students, medical assistants and interested laymen. 5th. Zuckschwerdt; Munich: 2008 | |
|
Directive 2010/63/EU, . Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. 2010, simpleeur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDFAccessed May 17, 2016. | |
|
European Medicines Agency. ICH-GCP: ICH Topic E6 (R1) Guideline for Good Clinical Practice. 2002, simpleeur-lex.europa.eu/legalcontent/EN/TXT/?uri=celex%3A32010L0063Accessed August 31, 2015. | |
|
National Institutes of Health. U.S. National Library of Medicine: Clinical Trial Phases. 2015, simpleclinicaltrials.govAccessed August 31, 2015. | |
|
Ciociola AA, Cohen LB and Kulkarni P: FDA-Related Matters Committee of the American College of Gastroenterology: How drugs are developed and approved by the FDA: Current process and future directions. Am J Gastroenterol. 109:620–623. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Khanna C, London C, Vail D, Mazcko C and Hirschfeld S: Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin Cancer Res. 15:5671–5677. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Monath TP, Kahn LH and Kaplan B: Introduction: One health perspective. ILAR J. 51:193–198. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Séveré S, Marchand P, Guiffard I, Morio F, Venisseau A, Veyrand B, Le Bizec B, Antignac JP and Abadie J: Pollutants in pet dogs: A model for environmental links to breast cancer. Springerplus. 4:272015. View Article : Google Scholar : PubMed/NCBI | |
|
Kelsey JL, Moore AS and Glickman LT: Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiol Rev. 20:204–217. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Hansen K and Khanna C: Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer. 40:858–880. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Fürdös I, Fazekas J, Singer J and Jensen-Jarolim E: Translating clinical trials from human to veterinary oncology and back. J Transl Med. 13:2652015. View Article : Google Scholar : PubMed/NCBI | |
|
Jensen-Jarolim E: Definition of comparative medicine: History and new identityComparative Medicine. Anatomy and Physiology. Springer; Wien: pp. 1–18. 2014 | |
|
Singer J and Jensen-Jarolim E: IgE-based immunotherapy of cancer-a comparative oncology approach. J Carcinog Mutagen. 5:10001762014. View Article : Google Scholar : PubMed/NCBI | |
|
Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G and Bocchini V: Cancer incidence in pet dogs: Findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med. 22:976–984. 2008. View Article : Google Scholar : PubMed/NCBI |
